Hepatocellular carcinoma is the 2nd most common cause of cancer-related deaths worldwide with steadily increasing morbidity and mortality. Loco-regional ablative therapies are potentially curative treatment options for the early disease stages and they can be used as a bridge to liver transplantation The purpose of our study is to assess the clinical, laboratory and radiological factors that may affect patients’ outcomes following loco-regional ablation of their HCCs.


221 patients were retrospectively recruited for this study, they underwent loco-regional ablation as a primary therapy at Mayo Clinic between January 2000 and September 2017.

Patients were then classified into three main groups according to the ablation technique used )(radiofrequency ablation, microwave ablation and Other ablations

Comparison of the overall survival and recurrence-free survival were performed between the three



Lymphocyte /monocyte ratio can be considered a novel and strong independent prognostic factor for Overall survival while  AFP is most important independent prognostic factor for recurrence-free survival  in hepatocellular carcinoma patients undergoing loco-regional ablation